secwatch.observer — SEC 8-K summary
======================================

Issuer:     OPKO HEALTH, INC. (OPK)
CIK:        0000944809
Form:       8-K
Filed at:   2025-10-29T23:59:59+00:00
Accession:  0001193125-25-256325
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OPKO Q3 net income $21.6M; Regeneron collaboration with $1B+ potential; sells BioReference oncology to Labcorp for $225M
--------------------------------------------------------------------------------

- Q3 consolidated revenues $151.7M, down 12.6% YoY; operating income $48.1M vs $14.2M; diluted EPS $0.03 flat.
- Entered multi-program Regeneron collaboration for multispecific antibodies; upfront plus milestones >$200M per program, total potential >$1B.
- Completed sale of BioReference oncology assets to Labcorp for $225M ($192.5M cash + $32.5M earnout); net gain of $101.6M recorded.
- Pharmaceuticals revenue $37.7M (Rayaldee $7.5M, up 29%); diagnostics revenue $95.2M, down due to prior-year asset sales.
- Cash, cash equivalents and restricted cash $428.9M at Sep 30, 2025; $73.8M used in share repurchase program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/944809/000119312525256325/0001193125-25-256325-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/944809/000119312525256325/opk-20251029.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-256325

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer